#United States #New York #Citius Pharmaceuticals #LYMPHIR #Citius Oncology

Citius Pharmaceuticals Engages with Investors at Upcoming Conferences

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a pioneering biopharmaceutical company focusing on the development of innovative critical care products, has announced its participation in two major investor conferences set for September 2026 in New York City. These events represent an excellent opportunity for the company to connect with potential investors and share vital updates regarding its product pipeline and market strategies.

Leadership Presentation

Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, will be leading the charge during these conferences. He will present insights into the company's operations and key developments, specifically focusing on the ongoing commercialization of LYMPHIR® (denileukin diftitox-cxdl), an essential product from Citius Oncology, Inc. (Nasdaq: CTOR), a subsidiary in which Citius holds a majority stake.

Overview of the Conferences

The first of the two events is the Moody Capital Solutions 2026 Disruptive Growth Life Sciences Conference, scheduled for September 9-10, 2026, at The Westin New York Grand Central. Mazur’s presentation is timed for Wednesday, September 9 at 3:15 PM.

Following this, Mazur will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, held at the Lotte New York Palace Hotel. His attendance at this event includes a presentation on Tuesday, September 15, from 2:00 PM to 2:30 PM.

Key Products in Focus

At these conferences, Mazur will delve deep into how Citius is not only advancing its existing products but is also laying the groundwork for future innovations within the healthcare sector. A highlight will be the focus on LYMPHIR®, a targeted immunotherapy launched in December 2025 which has been set to provide vital treatment options for adults suffering from relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

The market for LYMPHIR® is ambitious, currently estimated to surpass $400 million, indicating a strong demand that is yet to be fully met by existing therapies. Additionally, Citius is actively managing a robust late-stage pipeline featuring notable products like Mino-Lok® and CITI-002 (Halo-Lido).

Pipeline Updates

Mino-Lok®, a critical catheter lock solution aiming to salvage catheters in patients with related infections, has recently completed pivotal Phase 3 trials, exceeding its primary and secondary endpoints. This product showcases Citius’ commitment to developing solutions that can significantly alter patient care trajectories.

Meanwhile, Halo-Lido is also making strides with a Phase 2b trial reported in 2023, demonstrating Citius' proactive approach to addressing various healthcare needs. The company is engaged with the FDA to ascertain forthcoming steps for both programs in anticipation of commercializing these innovations.

Connect with Citius

Investors eager to meet the management team for personalized discussions can reach out through their conference representatives or directly through the investor relations team at Citius. Given the promising outlook and the products on the horizon, these upcoming conferences offer a pivotal moment for Citius Pharmaceuticals as it seeks to broaden its reach and solidify investor confidence in its future.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is dedicated to the pioneering development and commercialization of first-in-class critical care products. Holding about 62% ownership in Citius Oncology, the company is strategically positioned to capitalize on advancements in targeted immunotherapy, with a significant emphasis on market leadership in areas that demand innovative healthcare solutions. For more insights into their product lineup or investor relations, please visit Citius Pharmaceuticals.